JP2007526998A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007526998A5 JP2007526998A5 JP2006549676A JP2006549676A JP2007526998A5 JP 2007526998 A5 JP2007526998 A5 JP 2007526998A5 JP 2006549676 A JP2006549676 A JP 2006549676A JP 2006549676 A JP2006549676 A JP 2006549676A JP 2007526998 A5 JP2007526998 A5 JP 2007526998A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- values
- less
- formula
- glucuronide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53734104P | 2004-01-16 | 2004-01-16 | |
| PCT/US2005/001469 WO2005069900A2 (en) | 2004-01-16 | 2005-01-14 | Npc1l1 (npc3) and methods of identifying ligands thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007526998A JP2007526998A (ja) | 2007-09-20 |
| JP2007526998A5 true JP2007526998A5 (https=) | 2008-02-28 |
| JP4590417B2 JP4590417B2 (ja) | 2010-12-01 |
Family
ID=34807095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549676A Expired - Fee Related JP4590417B2 (ja) | 2004-01-16 | 2005-01-14 | Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7901893B2 (https=) |
| EP (1) | EP1723414A4 (https=) |
| JP (1) | JP4590417B2 (https=) |
| CA (1) | CA2553769C (https=) |
| MX (1) | MXPA06008124A (https=) |
| WO (1) | WO2005069900A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| US7135556B2 (en) | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| US20040132058A1 (en) * | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| ATE485267T1 (de) | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
| AU2004308332B2 (en) | 2003-12-23 | 2008-04-10 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| JP4590417B2 (ja) | 2004-01-16 | 2010-12-01 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法 |
| US7696177B2 (en) * | 2005-06-15 | 2010-04-13 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
| AR057072A1 (es) | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US7910698B2 (en) | 2006-02-24 | 2011-03-22 | Schering Corporation | NPC1L1 orthologues |
| TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| EP2173893A4 (en) * | 2007-06-28 | 2010-07-21 | Merck Sharp & Dohme | USE OF MDCK CELLS IN THE ASSESSMENT OF CHOLESTEROL MODULATORS |
| CN101580871B (zh) * | 2008-05-13 | 2013-06-05 | 中国科学院上海生命科学研究院 | 基于分析npc1l1蛋白亚细胞定位变化筛选降胆固醇新药的方法 |
| US8609098B2 (en) * | 2010-06-10 | 2013-12-17 | Adbiotech Co., Ltd. | Composition for repression of hyperlipidemia and obesity through suppression of intestinal cholesterol absorption |
| US10377815B2 (en) | 2015-05-05 | 2019-08-13 | Albert Einstein College Of Medicine | Bispecific antibodies and fusion proteins that bind to EBOV and NPC1 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2525125B2 (ja) * | 1991-07-23 | 1996-08-14 | シェリング・コーポレーション | 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法 |
| US5561227A (en) * | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
| US5688787A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| US5688785A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| LT3595B (en) * | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| WO1995001961A1 (en) * | 1993-07-09 | 1995-01-19 | Schering Corporation | Process for the synthesis of azetidinones |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5618707A (en) * | 1996-01-04 | 1997-04-08 | Schering Corporation | Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof |
| WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
| US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
| US5739321A (en) * | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
| US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| WO1999001555A1 (en) * | 1997-07-03 | 1999-01-14 | The United States Of America Represented By The Secretary, Department Of Health And Human Services | Genes for niemann-pick type c disease |
| US6133001A (en) * | 1998-02-23 | 2000-10-17 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone |
| US5919672A (en) * | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
| EP1137634B1 (en) | 1998-12-07 | 2005-06-15 | Schering Corporation | Process for the synthesis of azetidinones |
| US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
| CA2367289C (en) | 1999-04-05 | 2008-02-12 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(r)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl)]-4(s)-(4-hydroxyphenyl)-2-azetidinone |
| AR023463A1 (es) | 1999-04-16 | 2002-09-04 | Schering Corp | Uso de compuestos de azetidinona |
| CA2399776A1 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| EP1698697A3 (en) | 2000-03-24 | 2006-09-13 | Takeda Pharmaceutical Company Limited | SSD-containing protein, process for producing the same and use thereof |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| HU230253B1 (hu) * | 2001-01-26 | 2015-11-30 | Merck Sharp & Dohme Corp | Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére |
| DK1373230T3 (da) | 2001-03-28 | 2005-11-07 | Schering Corp | Enantiselektiv syntese af azetidinon mellemprodukter |
| WO2003100094A2 (en) | 2002-05-23 | 2003-12-04 | Devgen Nv | Method for determining the influence of a compound on cholesterol transport |
| CA2492017A1 (en) | 2002-07-19 | 2004-01-29 | Schering Corporation | Npc1l1 (npc3) and methods of use thereof |
| US20040137467A1 (en) * | 2002-07-19 | 2004-07-15 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| US20040132058A1 (en) * | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| EP1529061B1 (en) | 2002-08-06 | 2008-02-13 | Sanofi-Aventis Deutschland GmbH | Method for isolating an intestinal cholesterol binding protein |
| US20040171073A1 (en) | 2002-10-08 | 2004-09-02 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
| JP4590417B2 (ja) | 2004-01-16 | 2010-12-01 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法 |
| EP1789437A4 (en) | 2004-07-30 | 2008-11-05 | Sinai School Medicine | INHIBITORS OF NPC1L1 AND NPC1L1 AND METHODS OF USE THEREOF |
-
2005
- 2005-01-14 JP JP2006549676A patent/JP4590417B2/ja not_active Expired - Fee Related
- 2005-01-14 MX MXPA06008124A patent/MXPA06008124A/es unknown
- 2005-01-14 WO PCT/US2005/001469 patent/WO2005069900A2/en not_active Ceased
- 2005-01-14 US US10/586,310 patent/US7901893B2/en not_active Expired - Fee Related
- 2005-01-14 CA CA2553769A patent/CA2553769C/en not_active Expired - Fee Related
- 2005-01-14 EP EP05711542A patent/EP1723414A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007526998A5 (https=) | ||
| JP5700911B2 (ja) | 配向され、固定化された巨大分子を含む組成物とその製造法 | |
| JP2014532430A5 (https=) | ||
| JP2006517985A5 (https=) | ||
| JP2004514139A5 (https=) | ||
| ATE489482T1 (de) | Verfahren zur herstellung von hybridsubstraten mit dna und antikörpern sowie verwendungen davon | |
| JP2007517217A5 (https=) | ||
| DE602006019111D1 (de) | Verfahren zur isolierung von analyten aus einer probe | |
| JP2005206602A5 (https=) | ||
| ATE502117T1 (de) | Nanopartikel mit gebundenen oligonukleotiden und deren verwendungen | |
| WO2005023986A3 (en) | Microrna as ligands and target molecules | |
| ATE449337T1 (de) | Assay | |
| JP2007505908A5 (https=) | ||
| JP2021500551A5 (https=) | ||
| WO2005017205A3 (en) | Nucleic acid mapping using linear analysis | |
| ATE373235T1 (de) | Fluoreszensanalyseelement mit der anwendung eines metallischen nanolochs und verfahren zur herstellung desselben | |
| DE602005022797D1 (de) | Silanmoleküle mit voraktivierten und Protein-resistenten Funktionalitäten sowie diese enthaltende Silanschichten | |
| Tsai et al. | Fluorescent double-stranded DNA-templated copper nanoprobes for rapid diagnosis of tuberculosis | |
| CN103935985A (zh) | 石墨烯纳米网和在石墨烯片中形成孔的方法 | |
| Campuzano et al. | Tailoring sensitivity in electrochemical nucleic acid hybridization biosensing: Role of surface chemistry and labeling strategies | |
| JP2009539082A5 (https=) | ||
| ATE548467T1 (de) | Verfahren zur identifizierung von biomarkern mit eignung bei der diagnose biologischer zustände | |
| JP2017026631A5 (https=) | ||
| EP3828284A1 (en) | One-step procedure for the purification of nucleic acids | |
| WO2005069900B1 (en) | Npc1l1 (npc3) and methods of identifying ligands thereof |